Klas Gosta Wiman
Corporate Officer/Principal bei Karolinska Institutet
Aktive Positionen von Klas Gosta Wiman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | 15.05.2009 | - |
Karriereverlauf von Klas Gosta Wiman
Ehemalige bekannte Positionen von Klas Gosta Wiman
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| APREA THERAPEUTICS, INC. | Gründer | 01.01.2002 | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Direktor/Vorstandsmitglied | 01.01.2003 | - |
| Gründer | 01.01.2003 | - |
Statistik
International
| Schweden | 3 |
| Vereinigte Staaten | 2 |
Operativ
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Börse
- Insiders
- Klas Gosta Wiman
- Erfahrung
